Europace. 2026 Aug 4;28(8):euag214. doi: 10.1093/europace/euag214.
ABSTRACT
AIMS: Population-based screening for atrial fibrillation (AF) should be considered in elderly individuals to enable AF detection. However, participation in systematic screening programmes is often suboptimal. STROKESTOP III evaluated whether opportunistic screening could improve participation compared with systematic screening.
METHODS AND RESULTS: STROKESTOP III is a cluster-randomized trial including individuals aged 75-76 years from 16 primary care centres in Region Värmland, Sweden. Centres were randomized to systematic screening, using mailed invitations, or opportunistic screening, using invitations during visits.In the systematic arm, 1312 individuals were eligible and invited, of whom 607 participated (46.3%). In the opportunistic arm, 1390 individuals attended participating primary care centres and were potentially eligible for invitation. However, 641 individuals (46.1%) were not assessed for eligibility. Among the 749 assessed individuals, 609 were eligible and 374 participated.Participation among invited eligible individuals was significantly higher with opportunistic than systematic screening (374/609, 61.4% vs. 607/1,312, 46.3%; P < 0.005). However, overall reach was lower in the opportunistic arm because of incomplete assessment for invitation (374/1,479, 25.3% vs. 607/1,437, 42.2%; P < 0.005). Participants in the opportunistic arm had a higher cardiovascular risk burden, including more hypertension, diabetes, and a higher CHA2DS2-VASc-score (3.99 vs. 3.60; P < 0.005). Exclusion rates were higher (18.7% vs. 8.7%; P < 0.005), mainly due to previously diagnosed AF and cognitive impairment.
CONCLUSION: Opportunistic screening increased participation among invited individuals and identified a higher-risk population, but its overall population reach was limited by incomplete eligibility assessment. Combining opportunistic and systematic strategies may optimize reach and participation in AF screening programmes.
PMID:42669050 | DOI:10.1093/europace/euag214
